Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Synvisc (hylan G-F 20) Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

NCT02674399
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
JointStem, Synvisc-One
Drug
Lead sponsor
Nature Cell Co. Ltd.
Industry
Eligibility
22 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Santa Monica, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 2, 2026, 12:47 AM EDT
Not listed Not applicable Interventional

The Effectiveness of Hylan GF-20 on Joint Reaction Forces and Kinematic Patterns During Gait in Patients With Knee Osteoarthritis

NCT00147186
View directory record Official record
Conditions
Osteoarthritis
Interventions
Hylan G-F 20
Device
Lead sponsor
Kessler Foundation
Other
Eligibility
41 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 15, 2007 · Synced Oct 2, 2026, 12:47 AM EDT
Completed Phase 2 Interventional

Synvisc to Treat Osteoarthritis of the Temporomandibular Joint

NCT00078351
View directory record Official record
Conditions
Osteoarthritis
Interventions
High molecular weight hylan (Synvisc) injection
Procedure
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 12:47 AM EDT
Terminated Phase 4 Interventional Results available

Knee Injection RCT

NCT03694821
View directory record Official record
Conditions
Osteoarthritis
Interventions
Ketorolac Tromethamine Injection, Methylprednisolone Acetate Injection, Hylan G-F 20
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 2, 2026, 12:47 AM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip

NCT00131326
View directory record Official record
Conditions
Osteoarthritis, Hip, Musculoskeletal Diseases
Interventions
Synvisc (hylan G-F 20)
Device
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
35 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 2, 2026, 12:47 AM EDT
Terminated Not applicable Interventional Results available

Optimization of Synvisc-One for Knee OA

NCT02029703
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Synvisc-One Injection, Sham Injection
Device · Other
Lead sponsor
Elaine Husni
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 2, 2026, 12:47 AM EDT
Completed Not applicable Interventional Results available

An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study

NCT00198029
View directory record Official record
Conditions
Carpometacarpal Osteoarthritis
Interventions
Synvisc (hylan G-F20)
Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 95 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 2, 2026, 12:47 AM EDT
Terminated Phase 1 Interventional

Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity

NCT01810848
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Hylan G-F 20, Control
Device · Other
Lead sponsor
OhioHealth
Other
Eligibility
40 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 2, 2026, 12:47 AM EDT
Completed Phase 4 Interventional Results available

Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis

NCT01557868
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
hylan G-F 20, 1% sodium hyaluronate
Device
Lead sponsor
American Orthopaedic Society for Sports Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 2, 2026, 12:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Synvisc-One for Younger, Active Patients With Osteoarthritis

NCT01625013
View directory record Official record
Conditions
Osteoarthritis
Interventions
Synvisc-One (G-F 20)
Device
Lead sponsor
Anthony Luke
Other
Eligibility
30 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 2, 2026, 12:47 AM EDT
Completed Phase 4 Interventional

A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.

NCT00293163
View directory record Official record
Conditions
Facial Wrinkles
Interventions
Hylaform, Hylaform Plus (hylan B gel)
Device
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
3
States / cities
Los Angeles, California • Warren, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 2, 2026, 12:47 AM EDT
Withdrawn Not applicable Interventional

Study of Viscosupplementation for the Treatment of Knee Pain After Menisectomy

NCT00971074
View directory record Official record
Conditions
Arthralgia
Interventions
Hylan G-F 20, Sham Injection
Drug · Other
Lead sponsor
Grant Jones
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 2, 2026, 12:47 AM EDT
Completed Phase 3 Interventional Results available

A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb

NCT00398866
View directory record Official record
Conditions
Osteoarthritis
Interventions
Synvisc (Hylan G-F20; hyaluronan injection), Bupivicaine (local anesthesia injection), Kenalog (triamcinolone; corticosteroid injection)
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 2, 2026, 12:47 AM EDT
Completed Not applicable Interventional Results available

A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip

NCT01618708
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Synvisc-One (hylan G-F 20), Placebo
Device
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
35 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
45
States / cities
Burmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 2, 2026, 12:47 AM EDT
Completed No phase listed Observational

Outcome Following Hylan F- 20 (Synvisc) + Corticosteroid Injections for the Treatment of Osteoarthritis of the Knee

NCT00312533
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Hylan F- 20
Drug
Lead sponsor
Steadman Hawkins Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Oct 2, 2026, 12:47 AM EDT
Terminated Phase 4 Interventional Results available

Trial Comparing Three Single Dose Injections for Knee Osteoarthritis

NCT05492851
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Zilretta, Synvisc-One 48 MG in 6 ML Prefilled Syringe, Monovisc 88 MG Per 4 ML Prefilled Syringe
Drug
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Columbus, Ohio • Lewis Center, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 2, 2026, 12:47 AM EDT